Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PD-1
Biotech
Boehringer pays OSE $42M to grab new asset, expand into cardio
Boehringer will get a preclinical anti-PD1/cytokine drug as well as expand their solid tumor work into cardio-renal-metabolic diseases.
James Waldron
May 22, 2024 4:47am
New immunotherapy drug design ups survival in mice with cancer
Apr 23, 2024 3:40am
Dupixent for cancer? Researchers test med as PD-1 booster
Dec 7, 2023 6:00am
Gilead-Arcus' TIGIT gets high response in gastric cancer
Nov 7, 2023 9:40am
AbbVie and Calico drug boosts immunotherapy response in mice
Oct 5, 2023 11:19am
Agenus lays off 25%, sidelines programs to focus on cancer combo
Aug 23, 2023 11:04am